406 related articles for article (PubMed ID: 27666928)
1. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
2. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
4. Genistein sensitizes glioblastoma cells to carbon ions via inhibiting DNA-PKcs phosphorylation and subsequently repressing NHEJ and delaying HR repair pathways.
Liu X; Li P; Hirayama R; Niu Y; Liu X; Chen W; Jin X; Zhang P; Ye F; Zhao T; Liu B; Li Q
Radiother Oncol; 2018 Oct; 129(1):84-94. PubMed ID: 29685705
[TBL] [Abstract][Full Text] [Related]
5. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
7. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
8. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
9. The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions.
Gerelchuluun A; Manabe E; Ishikawa T; Sun L; Itoh K; Sakae T; Suzuki K; Hirayama R; Asaithamby A; Chen DJ; Tsuboi K
Radiat Res; 2015 Mar; 183(3):345-56. PubMed ID: 25738894
[TBL] [Abstract][Full Text] [Related]
10. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
11. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.
Chitnis MM; Lodhia KA; Aleksic T; Gao S; Protheroe AS; Macaulay VM
Oncogene; 2014 Nov; 33(45):5262-73. PubMed ID: 24186206
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
13. The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression.
Bee L; Fabris S; Cherubini R; Mognato M; Celotti L
PLoS One; 2013; 8(7):e69061. PubMed ID: 23874869
[TBL] [Abstract][Full Text] [Related]
14. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
15. Combining carbon ion irradiation and non-homologous end-joining repair inhibitor NU7026 efficiently kills cancer cells.
Ma H; Takahashi A; Yoshida Y; Adachi A; Kanai T; Ohno T; Nakano T
Radiat Oncol; 2015 Nov; 10():225. PubMed ID: 26553138
[TBL] [Abstract][Full Text] [Related]
16. DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines.
Sak A; Groneberg M; Stuschke M
Int J Radiat Biol; 2019 Sep; 95(9):1205-1219. PubMed ID: 31287365
[No Abstract] [Full Text] [Related]
17. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis.
Kasten-Pisula U; Windhorst S; Dahm-Daphi J; Mayr G; Dikomey E
Radiother Oncol; 2007 Jun; 83(3):296-303. PubMed ID: 17521756
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
20. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.
Oike T; Ogiwara H; Torikai K; Nakano T; Yokota J; Kohno T
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):815-21. PubMed ID: 22417805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
